A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects
Pharmaceuticals · 15.07.2026 · 19 (7) · 1089
DOI: 10.3390/ph19071089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 15.07.2026. Verfasst von Marcelo Gomes Davanço und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical & Clinical Affairs Department, United Medical Ltd. (A Knight Therapeutics Company), Sao Paulo 04085-001, SP, Brazil. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Laboratorio LKM Chile SpA (a Knight Therapeutics company)., Laboratorio LKM Chile SpA.
Abstract (Originalsprache)
Background
Multiple myeloma (MM) is a mature B-cell disorder characterized by the excessive production of monoclonal immunoglobulins. It is the second most common hematological cancer and predominantly affects older adults. In 2022, there were approximately 188,000 MM new cases worldwide. The disease is associated with a relapsing–refractory course. First-line therapies are often insufficient, making additional treatment options necessary. For patients refractory to lenalidomide and proteasome inhibitors (bortezomib and/or carfilzomib), pomalidomide combined with dexamethasone and an additional active agent can be used as a therapeutic strategy.
Objective
This study was conducted to evaluate the bioequivalence and tolerability of two pomalidomide hard capsule formulations to support regulatory approval of a branded generic product in Latin American countries.
Methods
An open-label, randomized, single-dose, two-treatment, two-sequence, two-period crossover study was conducted in healthy male subjects. Participants received a single oral dose of the test product, Xetrane® 4 mg hard capsule (Laboratório LKM S.A., Argentina), and the reference product, Imnovid® 4 mg hard capsule (Celgene International Sàrl), with a 7-day washout period. Blood samples were collected over 48 h post-dose. Plasma pomalidomide concentrations were determined using a validated LC-MS/MS method, and pharmacokinetic parameters were estimated using non-compartmental analysis.
Findings
Thirty-four subjects were enrolled, and 29 completed the study. Geometric mean ratios (90% confidence intervals) for Cmax and AUC0–t were 106.24% (100.77–112.00) and 94.67% (91.61–97.82), respectively. Both formulations were well tolerated. Bioequivalence between Xetrane® and Imnovid® was demonstrated in accordance with regulatory criteria. NCT07694011.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical & Clinical Affairs Department, United Medical Ltd. (A Knight Therapeutics Company), Sao Paulo 04085-001, SP, Brazil.
- Medical & Clinical Affairs Department, Knight Therapeutics Inc., Montreal, QC H4M 2P2, Canada.
- R&D Department, Laboratorio LKM S.A. (A Knight Therapeutics Company), Buenos Aires C1179, Argentina.
ORCID-Profile: Marcelo Gomes Davanço, Jessé Moisan
Förderung
- Laboratorio LKM Chile SpA (a Knight Therapeutics company).
- Laboratorio LKM Chile SpA
Zitieren
APA
Davanço, M. G., Vespasiano, T. P., Moisan, J., Gonzalez, O., Sarmiento, M., & Groleau, M. (2026). A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects. Pharmaceuticals, 19(7), 1089. https://doi.org/10.3390/ph19071089
Vancouver
Davanço MG, Vespasiano TP, Moisan J, Gonzalez O, Sarmiento M, Groleau M. A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects. Pharmaceuticals. 2026;19(7):1089. doi:10.3390/ph19071089
BibTeX
@article{Davano2026,
author = {Davanço, Marcelo Gomes and Vespasiano, Thaís Pereira and Moisan, Jessé and Gonzalez, Oscar and Sarmiento, Milesa and Groleau, Mélanie},
title = {A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {7},
pages = {1089},
doi = {10.3390/ph19071089}
}
EUVIMED